387 related articles for article (PubMed ID: 35838545)
21. Gene fusion neoantigens: Emerging targets for cancer immunotherapy.
Wang Y; Shi T; Song X; Liu B; Wei J
Cancer Lett; 2021 May; 506():45-54. PubMed ID: 33675984
[TBL] [Abstract][Full Text] [Related]
22. Indication-specific tumor evolution and its impact on neoantigen targeting and biomarkers for individualized cancer immunotherapies.
Lo AA; Wallace A; Oreper D; Lounsbury N; Havnar C; Pechuan-Jorge X; Wu TD; Bourgon R; Jones R; Krogh K; Yang GY; Zill OA
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599029
[TBL] [Abstract][Full Text] [Related]
23. Personalized neoantigen viro-immunotherapy platform for triple-negative breast cancer.
Brito Baleeiro R; Liu P; Chard Dunmall LS; Di Gioia C; Nagano A; Cutmore L; Wang J; Chelala C; Nyambura LW; Walden P; Lemoine N; Wang Y
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37586771
[TBL] [Abstract][Full Text] [Related]
24. Development of neoantigens: from identification in cancer cells to application in cancer vaccines.
Ebrahimi N; Akbari M; Ghanaatian M; Roozbahani Moghaddam P; Adelian S; Borjian Boroujeni M; Yazdani E; Ahmadi A; Hamblin MR
Expert Rev Vaccines; 2022 Jul; 21(7):941-955. PubMed ID: 34196590
[TBL] [Abstract][Full Text] [Related]
25. Cancer immunotherapy targeting neoantigens.
Lu YC; Robbins PF
Semin Immunol; 2016 Feb; 28(1):22-7. PubMed ID: 26653770
[TBL] [Abstract][Full Text] [Related]
26. Neoantigen cancer vaccines: a new star on the horizon.
Li X; You J; Hong L; Liu W; Guo P; Hao X
Cancer Biol Med; 2023 Dec; 21(4):274-311. PubMed ID: 38164734
[TBL] [Abstract][Full Text] [Related]
27. Toward in silico Identification of Tumor Neoantigens in Immunotherapy.
Zhou C; Zhu C; Liu Q
Trends Mol Med; 2019 Nov; 25(11):980-992. PubMed ID: 31494024
[TBL] [Abstract][Full Text] [Related]
28. Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors.
Chen F; Zou Z; Du J; Su S; Shao J; Meng F; Yang J; Xu Q; Ding N; Yang Y; Liu Q; Wang Q; Sun Z; Zhou S; Du S; Wei J; Liu B
J Clin Invest; 2019 May; 129(5):2056-2070. PubMed ID: 30835255
[TBL] [Abstract][Full Text] [Related]
29. Identification of shared neoantigens in esophageal carcinoma by the combination of comprehensive analysis of genomic data and in silico neoantigen prediction.
Yuan Y; Chen C; Liu S; Xiong H; Huang Y; Zhang X; Zhang X; Li B
Cell Immunol; 2022 Jul; 377():104537. PubMed ID: 35636066
[TBL] [Abstract][Full Text] [Related]
30. Driving neoantigen-based cancer vaccines for personalized immunotherapy into clinic: A burdensome journey to promising land.
Yu G; He X; Li X; Wu Y
Biomed Pharmacother; 2022 Sep; 153():113464. PubMed ID: 36076493
[TBL] [Abstract][Full Text] [Related]
31. MHC class II restricted neoantigen: A promising target in tumor immunotherapy.
Sun Z; Chen F; Meng F; Wei J; Liu B
Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443
[TBL] [Abstract][Full Text] [Related]
32. Tumor neoantigens: from basic research to clinical applications.
Jiang T; Shi T; Zhang H; Hu J; Song Y; Wei J; Ren S; Zhou C
J Hematol Oncol; 2019 Sep; 12(1):93. PubMed ID: 31492199
[TBL] [Abstract][Full Text] [Related]
33. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
34. Personalized neoantigen vaccines: A new approach to cancer immunotherapy.
Aldous AR; Dong JZ
Bioorg Med Chem; 2018 Jun; 26(10):2842-2849. PubMed ID: 29111369
[TBL] [Abstract][Full Text] [Related]
35. A proteogenomic approach to target neoantigens in solid tumors.
Verma A; Halder A; Marathe S; Purwar R; Srivastava S
Expert Rev Proteomics; 2020; 17(11-12):797-812. PubMed ID: 33491499
[TBL] [Abstract][Full Text] [Related]
36. Neoantigen: A Promising Target for the Immunotherapy of Colorectal Cancer.
Zheng Y; Fu Y; Wang PP; Ding ZY
Dis Markers; 2022; 2022():8270305. PubMed ID: 35211210
[TBL] [Abstract][Full Text] [Related]
37. Neoantigen vaccine platforms in clinical development: understanding the future of personalized immunotherapy.
Supabphol S; Li L; Goedegebuure SP; Gillanders WE
Expert Opin Investig Drugs; 2021 May; 30(5):529-541. PubMed ID: 33641576
[TBL] [Abstract][Full Text] [Related]
38. Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Linette GP; Becker-Hapak M; Skidmore ZL; Baroja ML; Xu C; Hundal J; Spencer DH; Fu W; Cummins C; Robnett M; Kaabinejadian S; Hildebrand WH; Magrini V; Demeter R; Krupnick AS; Griffith OL; Griffith M; Mardis ER; Carreno BM
Proc Natl Acad Sci U S A; 2019 Nov; 116(47):23662-23670. PubMed ID: 31685621
[TBL] [Abstract][Full Text] [Related]
39. Shared neoantigens: ideal targets for off-the-shelf cancer immunotherapy.
Zhao W; Wu J; Chen S; Zhou Z
Pharmacogenomics; 2020 Jun; 21(9):637-645. PubMed ID: 32423288
[TBL] [Abstract][Full Text] [Related]
40. Advancing nanotechnology for neoantigen-based cancer theranostics.
Zou J; Zhang Y; Pan Y; Mao Z; Chen X
Chem Soc Rev; 2024 Apr; 53(7):3224-3252. PubMed ID: 38379286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
